Extracellular superoxide dismutase (EC-SOD, SOD3) protects tissues against oxidative damage by detoxifying superoxide anions, particularly in the lungs and cardiovascular system. EC-SOD undergoes several posttranslational modifications including N-glycosylation and proteolytic cleavage. While the roles of proteolytic cleavage have been well studied, the structure and function of EC-SOD N-glycans are poorly understood. Here we analyzed glycan structures on native EC-SOD purified from human sera, and identified sialylated biantennary structures. Using glycan maturation-defective CHO mutant cells, we further revealed that the presence of terminal sialic acids in the N-glycans of EC-SOD enhanced both the secretion and furin-mediated C-terminal cleavage of EC-SOD. These results provide new insights into how the posttranslational modifications of EC-SOD control its functions.
Introduction
Detoxification of reactive oxygen species is critically involved in the development of various human diseases, including cancer, neurodegenerative diseases, cardiovascular diseases and chronic obstructive pulmonary disease (COPD) (Valentine et al. 2005; Young et al. 2006; Halliwell 2007; Lei et al. 2015) . Superoxide dismutases (SODs), which convert superoxide anions to H 2 O 2 , play central roles in the detoxification of reactive oxygen species and protecting cells and organs from oxidative damage (McCord and Fridovich 1969; Fridovich 1995) . Indeed, SOD gene knockout mice exhibited various phenotypes and abnormalities, such as early lethality (Li et al. 1995; Gongora et al. 2008 ) and spontaneous development of cancer (Elchuri et al. 2005) , demonstrating that SODs are required for maintaining healthy tissues and organisms.
Mammalian SOD isozymes consist of three members, Cu/Zn-SOD (SOD1), Mn-SOD (SOD2) and extracellular SOD (EC-SOD, SOD3) (Zelko et al. 2002) . Based on their different enzymatic properties and localization, these three isozymes play different roles in vivo. For instance, Cu/Zn-SOD is known to be profoundly involved in the development of amyotrophic lateral sclerosis (Valentine et al. 2005) , and Mn-SOD is related to cardiomyopathy, which was revealed by knockout mouse and SNP studies (Li et al. 1995; Hiroi et al. 1999) . EC-SOD, the focus of this study, is highly expressed in the lung and blood vessels (Oury et al. 1994; Fattman et al. 2003 Fattman et al. , 2006 , and EC-SOD-deficient mice showed lung vulnerability, such as spontaneous development of emphysema and higher sensitivity to asbestos exposure (Fattman et al. 2006; Gongora et al. 2008; Yao et al. 2010) , indicating its patho-physiological importance in lung function.
In addition, EC-SOD is the only isozyme that is secreted from cells (Marklund et al. 1982; Tibell et al. 1987 ) and undergoes various posttranslational modifications through the secretory pathway, including N-glycosylation (Stromqvist et al. 1991; Edlund et al. 1992) , disulfide bond formation (Petersen et al. 2003 (Petersen et al. , 2008 and proteolytic cleavage (Enghild et al. 1999; Olsen et al. 2004 ) ( Figure 1A ). In particular, cleavage near the C-terminus has been well studied and found to have a significant impact on the tissue anchorage of EC-SOD and its excretion into bodily fluids. In the Cterminal part, EC-SOD has a heparin binding domain (HBD) consisting of a cluster of basic amino acids ( Figure 1A) , and a major fraction of EC-SOD is anchored to the extracellular matrix via interactions between HBD and molecules in the extracellular matrix including heparan sulfate proteoglycans and hyaluronan (Adachi et al. 1992; Sandstrom et al. 1992; Gao et al. 2008) . Cleavage removes the HBD and is considered to promote its excretion due to the loss of affinity for heparin (Sandstrom et al. 1994; Enghild et al. 1999; Olsen et al. 2004 ). Moreover, a genetic mutation in the HBD (R213G) was found to drastically reduce the heparin binding affinity (Adachi et al. 1996) and increase the level of serum EC-SOD 10-fold (Sandstrom et al. 1994) , leading to an increased risk of cardiovascular disease (Juul et al. 2004 ) and a decreased risk of COPD (Young et al. 2006; Dahl et al. 2008) . Although the regulation mechanisms for this cleavage are not understood, cleavage was found to be mediated in a two-step manner first by furin-like protease and subsequently by carboxypeptidase (Olsen et al. 2004) . In contrast to the well-studied proteolysis, however, little is known about the structure, function and regulation of the N-glycans of EC-SOD. Our aim was to clarify the mechanism by which EC-SOD functions are modulated by its N-glycan and examine whether the EC-SOD Nglycan is a target for therapy or biomarker discovery particularly in lung diseases such as COPD and lung cancer.
Glycosylation in general regulates numerous physical and functional properties of the proteins to which the glycans are attached, such as protein folding, enzyme activity, localization and interactions with other molecules (Moremen et al. 2012 ). Thus, changes or defects in specific glycan structures cause various phenotypic abnormalities and diseases (Ohtsubo and Marth 2006; Varki 2017) . Although the detailed structures of EC-SOD glycan are poorly understood, we recently found that deletion of the whole N-glycan on EC-SOD by mutating the single consensus glycosylation site (N89) results in the abolishment of secretion of EC-SOD in cultured cells (Ota et al. 2016) . Moreover, another report also showed that removal of N-glycan from EC-SOD by mutagenesis affected heparin binding affinity . These results suggested that the glycan modification critically regulates the intracellular behavior of EC-SOD, leading to the possibility that further glycobiology studies may unveil novel functions of EC-SOD glycan and their potential for therapeutic applications.
In this study, we determined the N-glycan structures of native EC-SOD purified from human serum. We further demonstrated that the terminal sialic acid (Sia) residues on its glycan positively regulate the furin-mediated C-terminal cleavage and secretion of EC-SOD. These results underscore the functional importance of this specific part of the glycan of EC-SOD, providing mechanistic insights into how glycosylation is involved in balancing a redox state through regulation of EC-SOD behavior.
Results
Native EC-SOD in human serum is modified with a sialylated biantennary glycan
To first determine the glycan structures of native EC-SOD, we purified it from pooled human sera by immunoprecipitation (IP). A western blot of the immunoprecipitates showed that two forms of EC-SOD exist in human serum ( Figure 1B, left, arrowheads) . It has a single N-glycosylation site at Asn89. The heparin binding domain (HBD) and the potential furincleavage sites are located near the C-terminus. A mutation naturally occurs at Arg213. (B) EC-SOD was immunoprecipitated from human sera and subjected to SDS-PAGE, western blotting or silver staining. The EC-SOD bands were excised from PVDF membrane and subjected to glycan MS analysis. Control experiments were performed with normal rabbit IgG. (C) Base peak chromatograms (BPCs) are shown for the MS analysis of EC-SOD alditol N-glycans or the control IP sample with normal IgG. Identified structures of the two major N-glycans of EC-SOD are shown. (D) Human serum proteins were treated with PNGase F and neuraminidase to remove whole N-glycans and terminal sialic acids, respectively, and were then analyzed by western blotting. This figure is available in black and white in print and in color at Glycobiology online.
Previous reports revealed that the two forms in human serum consist of the intact and the C-terminally cleaved forms (Olsen et al. 2004 ). The EC-SOD bands (including both upper and lower bands) on PVDF membrane transferred from an SDS-PAGE gel ( Figure 1B , right) were excised, and their N-glycans were released and analyzed by LC-MS ( Figure 1C and Supplementary Figure S1 ). As a control, a piece of membrane at the same position from the control IP sample with normal rabbit IgG was also analyzed. Two major glycan peaks were observed for the EC-SOD IP sample, and their structures were identified by comparing their retention times on a graphitized carbon column by LC (Pabst et al. 2007 ) and extracted ion chromatogram (EIC) MS patterns (Supplementary Figure S1) to those of established standard glycoproteins, bovine fetuin (Green et al. 1988; Townsend et al. 1989 ) and human α1-antitrypsin (Kolarich et al. 2006) . The identified N-glycan structures of EC-SOD in human serum were sialylated biantennary glycans with various sialic acid (Sia) linkages and the presence or absence of core fucose (Figure 1C, upper) . By contrast, no glycan signals were detected from the control sample ( Figure 1C , lower), confirming that the identified glycans were derived from precipitated EC-SOD. We found that the two EC-SOD bands in the SDS-PAGE gel were both sensitive to PNGase F that cleaves whole N-glycans and also to neuraminidase that removes only terminal sialic acids ( Figure 1D ). This suggested that the two bands were derived from the presence or absence of the Cterminal cleavable region. Furthermore, our western and lectin blotting show that the upper band seems to be stained with probes for α2,3-linked sialic acid much more than the lower band, suggesting that the two forms have different glycan structures (Supplementary Figure S2) . Although signal intensities of the upper and lower bands differ between Figure 1B and D, this probably reflects the differences in cleavage between individuals as discussed below.
Secretion and C-terminal cleavage of EC-SOD are affected in glycan maturation-defective cells
We next examined how glycan modification regulates EC-SOD function and behavior. Previous reports from our groups and others revealed that a non-glycosylation mutant exhibited lower thermal stability, defects in secretion, and higher binding affinity to heparin Ota et al. 2016) . We proposed that these functional alterations may be due to the loss of specific parts of the N-glycans, such as the sialic acid residue, but previous studies employing mutation strategies at the N-glycosylation site have not addressed this issue. To examine the roles of specific glycan structures of EC-SOD, we used mutant CHO cell line Lec1 in which N-glycan maturation is defective due to the loss of the key glycosyltransferase GnT-I (Stanley et al. 1975; Kumar et al. 1992) , meaning that all N-glycans were synthesized as oligomannose types (Figure 2A) .
We first examined whether secretion of EC-SOD was affected by the defect in glycan maturation. When overexpressed in these cells, EC-SOD is secreted into the culture medium and different gel mobilities were observed between the CHO and Lec1 samples derived from different glycan modifications ( Figure 2B ). We found that the rate of secretion of EC-SOD expressed in Lec1 cells was lower than that in parental CHO cells ( Figure 2C ). This suggested that the matured complex glycan is required for efficient secretion of EC-SOD.
The fact that the non-glycosylated mutant EC-SOD showed altered binding affinity to heparin suggested that EC-SOD glycans might affect the behavior of the C-terminal region that includes the HBD. As potential furin-cleavage sites are also located near the C-terminus, we hypothesized that furinmediated cleavage could also be affected by EC-SOD glycosylation. To test this possibility, furin was co-overexpressed with EC-SOD in CHO or Lec1 cells. To see a band shift clearly after furin-mediated cleavage, EC-SOD with a C-terminal myc-his tag was used. Exogenous expression of furin caused a prominent increase in a lower band evident in a western blot of the culture media ( Figure 3A) , confirming that furin cleaves EC-SOD in these cells. Moreover, the ratio of cleaved to total EC-SOD in the media was lower in Lec1 cells than in CHO cells ( Figure 3B ). This indicated that furinmediated cleavage is regulated by EC-SOD glycan in a glycan structure-dependent manner and that the mature complex form enhances cleavage.
To explain the mechanism of glycan-dependent alteration of the cleavage process, one possibility is that the difference in glycan structure has an effect on the direct recognition of EC-SOD by furin. To explore this possibility, EC-SOD purified from CHO or Lec1 cells was incubated with recombinant furin in the presence of Ca 2+ , enabling us to examine the direct cleavage of EC-SOD by furin in vitro. The addition of furin resulted in a lower band evident in a western blot ( Figure 3C ), as in the case of the cell experiments, revealing that furin directly cleaves EC-SOD. Moreover, we found that the cleavage was slower for Lec1-derived EC-SOD than for CHO-derived EC-SOD ( Figure 3D ). This indicated that the presence of complex type glycan on EC-SOD directly enhances the cleavage reaction mediated by furin protease.
Secretion and C-terminal cleavage of EC-SOD are enhanced by terminal sialic acid residues
To locate more specifically the part of the glycan that promotes secretion and furin-mediated cleavage, we next used another CHOderived cell line, Lec2, which is defective in terminal sialylation due to impairment of the CMP-Sia transporter (Stanley and Siminovitch 1977; Deutscher et al. 1984 ) ( Figure 4A ). We found that the ratio of secreted/total EC-SOD was significantly lower in Lec2 cells than CHO cells ( Figure 4B ), as was the case for Lec1 cells, revealing that the terminal sialic acids are key for the efficient secretion of EC-SOD. Next, to determine whether the furin-mediated cleavage is also regulated by terminal sialylation, EC-SOD was co-expressed with furin in CHO and Lec2 cells, and the proteins in the cells and the media were analyzed by western blotting ( Figure 4C ). As expected, furin-dependent production of the cleaved form of EC-SOD in the media was lower in Lec2 cells than in CHO cells, as observed in Lec1 cells ( Figure 3A) . Furthermore, reduced cleavage of EC-SOD by furin was also observed in in vitro cleavage assays ( Figure 4D ). Collectively, these results indicated that the terminal sialic acid residues on EC-SOD N-glycan are specifically involved in the promotion of furin-mediated cleavage and secretion into the extracellular space.
Discussion
In this study, we revealed that the mature form of the N-glycan of EC-SOD containing sialic acid residues positively regulates secretion and furin-mediated C-terminal cleavage of EC-SOD. Previous studies also showed that non-glycosylated EC-SOD exhibits impaired secretion and higher affinity to heparin but normal catalytic activity Ota et al. 2016 ). These results demonstrated that EC-SOD N-glycan indirectly modifies EC-SOD function by modulating its proteolysis and secretion but not enzymatic activity. -beads. The purified EC-SOD was incubated with different amounts of recombinant furin to allow for cleavage in vitro. Signal intensities of the cleaved EC-SOD were quantified and are shown as a graph (n = 5). All values are the mean ± SEM (*P < 0.05, Student's t-test). This figure is available in black and white in print and in color at Glycobiology online. predominant structure was disialylated biantennary glycan with core-fucose, which is the same structure as that determined for native EC-SOD in the present study. The identified structures from native EC-SOD show variations in the linkage of sialic acids (α2,3 and α2,6-linked) ( Figure 1C) , and it is possible that the promotive function of sialic acid for furin-mediated cleavage is linkage specific. Considering that CHO cells are known to produce only α2,3-linked sialic acid, not α2,6-linked sialic acid (Lee et al. 1989; Xu et al. 2011) , at least α2,3-linked sialic acids on EC-SOD glycan are functional in terms of the regulation of secretion and cleavage. As native EC-SOD was also found to be modified with α2,6-sialylated glycans ( Figure 1C ), it will be an interesting future challenge to see how the cleavage and secretion are changed when the linkage of sialic acids is altered. Although the regulation mechanisms are unclear for determining the ratio of sialic acid linkages on EC-SOD glycan in the human body, it may alter depending on factors such as disease and exogenous stimuli. Moreover, although we previously showed that core fucose modification of EC-SOD is unlikely involved in regulation of EC-SOD secretion (Ota et al. 2016) , the amount of core fucose could also be disregulated by diseases. Our next goal is to clarify how changes in the glycan structure of EC-SOD, such as the amount or linkage of sialic acid and core fucose, reflect disease states.
As shown in Figure 1B and D, the ratio of intact (upper) to cleaved (lower) forms of EC-SOD in human serum can differ. This is probably due to variations between batches of pooled sera, suggesting that C-terminal cleavage is differentially regulated depending on the individual. Although C-terminal cleavage itself and its impact on heparin binding have been well studied Enghild et al. 1999; Olsen et al. 2004) , it remains unclear how cleavage is regulated. Here, for the first time, we showed that specific glycan structures, particularly, the terminal sialic acids, are regulatory factors affecting C-terminal cleavage. Moreover, accumulating evidence revealed that the C-terminal cleavage is regulated by multiple factors, such as cellular redox states and oligomeric states of EC-SOD (Gottfredsen et al. 2012 ). In addition, the cleavage of EC-SOD is suggested to be a two-step event mediated by furin-like activity and an unknown B-type carboxypeptidase (Olsen et al. 2004 ). This indicates that the cleavage of EC-SOD is not a simple but a complex process regulated by multiple factors including glycosylation.
Our in vitro cleavage assay showed that the presence of complex type glycan on EC-SOD directly enhanced the cleavage by furin. Considering that the cleavage site is located near the C-terminus, we reasoned that the glycan, particularly the sialic acids, probably interact with the C-terminal region. Although the crystal structure of glycosylated EC-SOD produced from CHO cells has already been reported (Antonyuk et al. 2009 ), both the C-terminal region including the furin-cleavage sites and the glycan were not visible probably due to their flexibility. To estimate whether sialic acids on the EC-SOD glycan are spatially able to interact with the C-terminal region, we constructed a model of EC-SOD with a disialylated biantennary glycan (Supplementary Figure S3) based on the crystal structure of the EC-SOD tetramer (Antonyuk et al. 2009 ). Although Arg205 (visible C-terminal end) and Asn89 (N-glycosylation site) are relatively distant (28Å), the size and flexibility of the glycan mean that it is possible that the terminal sialic acids make contact with the Cterminal region. Considering the negative charge of the sialic acids and the cluster of basic amino acids in the C-terminal region, sialylated glycans might interact with the C-terminal region, leading to promotion of substrate recognition by furin.
In conclusion, we demonstrate that the N-glycan of EC-SOD regulates its functions, unveiling a novel molecular link between redox regulation and glycosylation. As increased EC-SOD levels in the serum resulting from gene mutation (R213G) had a considerable impact on the risk of COPD and cardiovascular disease (Juul et al. 2004; Young et al. 2006; Dahl et al. 2008) , regulation of the secretion and cleavage of EC-SOD by its N-glycan could also be related to the onset or progression of these diseases. Our next goal is to identify the factors that determine and alter the glycan structures of EC-SOD. Such studies may contribute further to our understanding of the functions of EC-SOD as well as the development of novel biomarkers and therapeutic strategies for the related diseases.
Materials and methods

Antibodies and lectins
Anti-furin antibody was purchased from R&D Systems (AF3420) and anti-GAPDH was from Millipore (MAB374). Anti-α2,3Sia antibody (HYB4) was from Wako. Biotinylated Maakia Amurensis Lectin (MAM) was purchased from Seikagaku Corporation (300,424). Anti-EC-SOD antibody was raised in rabbits against recombinant full-length non-tagged human EC-SOD that was stably expressed in CHO cells and purified from the culture media through heparin affinity and hydroxyapatite chromatography. The IgG fraction in rabbit antiserum was purified by ammonium sulfate precipitation and affinity chromatography with protein G resin, according to standard methods.
Immunopurification of EC-SOD from human sera
Human pooled serum (Kohjin-Bio) (1 mL) was first incubated with protein G Sepharose 4 Fast Flow (GE Healthcare) to remove serum IgG and associated proteins. The resultant sera were subjected to immunoprecipitation with anti-EC-SOD IgG-or normal rabbit IgG (Cappel)-conjugated M-280 Tosylactivated Dynabeads ® (ThermoFisher Scientific). The purified proteins were subjected to SDS-PAGE and glycan structural analysis.
SDS-PAGE, silver staining, lectin and western blot
These experiments were carried out as described previously (Ota et al. 2016) . SDS-PAGE was conducted using 8%, 10% or 5-20% gradient polyacrylamide gels. Silver staining was performed using the Silver Stain MS Kit (Wako) according to the manufacturer's protocol.
Glycan structural analysis
EC-SOD immunoprecipitated from human serum was separated by SDS-PAGE, and then proteins on the gel were transferred to PVDF membrane. The PVDF membrane was washed three times with water for 1 min each. The protein on the membrane was stained for 5 min with Direct Blue 71 (800 μL solution A: 0.1% (w/v) Direct Blue 71 (Sigma-Aldrich) in 10 mL solution B: acetic acid: ethanol: water = 1:4:5). After destaining with solution B for 1 min, the PVDF membrane was dried at room temperature for 4 h. The EC-SOD band and the corresponding portion from the control normal IgG sample were excised from the membrane and then placed in separate wells of a 96-well microtiter plate. The bands were then covered with 100 μL of 1% (w/v) poly(vinylpyrrolidone) 40,000 in 50% (v/v) methanol, agitated for 20 min, and washed with water (100 μL × five times). The release of N-glycans by PNGase F, reduction into alditol N-glycans and desalting using a cation-exchange column were all performed according to the method of Nakano et al. (Nakano et al. 2011 ) with some modifications. The alditol N-glycans were analyzed by LC-MS according to our previously reported procedure (Kizuka et al. 2015 
Glycosidase treatment
Serum EC-SOD was immunoprecipitated with EC-SOD antibody conjugated with Dynabeads ® as described above. For PNGase F treatment, proteins were denatured by boiling for 5 min in 20 μL of PBS with 1% SDS, 1% β-mercaptoethanol and 20 mM EDTA, and the sample was scaled up to 100 μL with PBS containing 1% Triton-X100 (final concentration). The sample (50 μL) was incubated with 1000 U of PNGase F (New England Biolabs) at 37°C for 3 h. For neuraminidase treatment, the beads were incubated with 80 mU Arthrobacter ureafaciens neuraminidase (Nacalai) in 100 mM acetic acid buffer, pH 5.5 at 37°C for 3 h. The enzyme reactions were stopped by adding sample buffer (with β-mercaptoethanol) and boiling for 5 min.
Plasmid construction
The full-length cDNA encoding human EC-SOD with a C-terminal myc-His tag was constructed as described previously (Ota et al. 2016) . Furin cDNA was amplified by PCR using reverse-transcribed total RNA of HEK293T cells as a template with primers 5′-GCCACCAT GGAGCTGAGGCCCTGGTTGCTAT and 5′-GAGGGCGCTCT GGTCTTTGATAAAG, and cloned into pCR ® -Blunt vector (ThermoFisher Scientific), and then subcloned into pcDNA6/myc-His A between the HindIII and XhoI sites.
Cell culture and transfection
CHO, Lec1 and Lec2 cells were cultured in MEMα supplemented with 10% fetal bovine serum. Cells were transfected with plasmids using Lipofectamine2000 (ThermoScientific) or polyethyleneimine MAX (Polyscience) as described previously (Ota et al. 2016) . After 7 h of transfection, the culture media were replaced with Opti-MEM I. At 24 h posttransfection, cells and culture medium were collected. Cells were lysed with PBS containing 1% Triton X-100 and a protease inhibitor cocktail, and the lysates were subjected to further analysis. To precipitate proteins secreted into the culture media, 1/30 volumes of 5 M NaCl and 2.5 volumes of ethanol were added, followed by cooling at −30°C. The proteins were centrifuged at 11,000 × g for 30 min, and the pellets were washed with 70% ethanol, followed by centrifugation again for 10 min. The final pellets were then dissolved with Laemmli sample buffer.
In vitro furin-cleavage assay CHO, Lec1 or Lec2 cells were transfected with the plasmid encoding EC-SOD-myc-his as described above. After 7 h, the media were replaced with Opti-MEM I, followed by 2 days of culture. Secreted EC-SOD-myc-his was trapped with Ni Sepharose 6 Fast Flow (GE Healthcare) at 4°C for 3 h, and the beads were washed with binding buffer (20 mM sodium phosphate, 5 mM imidazole, 500 mM NaCl, pH 7.4) twice, and then directly used for the cleavage assay. The beads were incubated with recombinant human furin (R&D Systems) in TBS pH 7.4 containing 1 mM CaCl 2 for 3 h at 37°C.
Structural modeling of glycosylated EC-SOD
Glycosylated human EC-SOD was modeled with GlyProt (http:// www.glycosciences.de/glyprot/) using the crystal structure of human EC-SOD (PDB ID 2JLP) (Antonyuk et al. 2009 ). The resulting image was prepared using PyMol software (http://www.pymol.org/).
Supplementary data
Supplementary data is available at Glycobiology online. 
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